Otsuka Tatsui, Togo Takashi, Sugiyama Naoya, Uehara Kumi, Yoshimi Asuka, Karashima Aya, Shioya Hiromi, Hirayasu Yoshio
Department of Psychiatry, Yokohama City University School of Medicine: 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):564-6. doi: 10.1016/j.pnpbp.2006.10.014. Epub 2006 Dec 12.
Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT(2A) and dopamine D(2) receptors, as well as a unique agonist effects on serotonin 5-HT(1A) receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.
强迫症（OCD）常并发抑郁症。我们报告了一名对治疗难治的强迫症和对治疗难治的重度抑郁症患者，该患者对帕罗西汀联合哌罗匹隆增效治疗表现出强烈反应。哌罗匹隆是一种第二代抗精神病药物，对5-羟色胺5-HT(2A)和多巴胺D(2)受体均有拮抗作用，对5-羟色胺5-HT(1A)受体有独特的激动作用。未来的研究对于阐明选择性5-羟色胺再摄取抑制剂联合哌罗匹隆增效治疗难治性强迫症伴抑郁症的效用将具有重要价值。
